Clinical Trial News Archive - July 2025
July 1, 2025
July 7, 2025
July 9, 2025
- Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine
- FDA Grants Fast Track Designation for TRE-515 in Combination with Radiation Therapy for the Treatment of Metastatic Castration Resistant Prostate Cancer
July 11, 2025
July 14, 2025
- Baxdrostat Met the Primary and All Secondary Endpoints in BaxHTN Phase III Trial in Patients with Uncontrolled or Treatment Resistant Hypertension
- Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill MK-8527
- Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1
July 15, 2025
- Shorla Oncology Announces FDA Orphan Drug Designation for SH-110 to Treat Rare Brain Cancer Using Oral Liquid
- Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA
- Shorla Oncology Announces FDA Orphan Drug Designation for SH-110 to Treat Rare Brain Cancer Using Oral Liquid
July 16, 2025
July 17, 2025
- Johnson & Johnson Receives U.S. FDA Priority Review for TAR-200 NDA in High-Risk Non-Muscle Invasive Bladder Cancer
- Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies
July 18, 2025
July 20, 2025
July 21, 2025
July 22, 2025
July 23, 2025
- Apnimed Reports Positive Topline Results from Second Phase 3 Trial of AD109, Reinforcing Potential of First Oral Pill for Obstructive Sleep Apnea
- Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib
- Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping
July 24, 2025
- Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer
- Gefurulimab Dual-Binding Nanobody Demonstrated Statistically Significant and Clinically Meaningful Improvement in Functional Activities of Daily Living in Adults with Generalised Myasthenia Gravis in PREVAIL Phase III Trial
July 25, 2025
July 29, 2025
- Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)
- Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma
- Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata
July 30, 2025
July 31, 2025
Clinical trial results archive
- 2025
- January, February, March, April, May, June, July, August
- 2024
- January, February, March, April, May, June, July, August, September, October, November, December
- 2023
- January, February, March, April, May, June, July, August, September, October, November, December
- 2022
- January, February, March, April, May, June, July, August, September, October, November, December
- 2021
- January, February, March, April, May, June, July, August, September, October, November, December
- 2020
- January, February, March, April, May, June, July, August, September, October, November, December
- 2019
- January, February, March, April, May, June, July, August, September, October, November, December
- 2018
- January, February, March, April, May, June, July, August, September, October, November, December
- 2017
- May, June, July, August, September, October, November, December
- 2016
- October
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.